1 (1)

J.

: de

S. S. S. S.

20

25

30

35

US CLAIMS

- 1. A method for determining, in vitro, predisposition to a venous thromboembolic disease in an individual, in which it is determined whether the individual has been infected with a bacterium of the Chlamydia genus, in particular Chlamydia pneumoniae.
- 10 2. The method as claimed in claim 1, in which it is determined whether the individual has been infected with a bacterium of the Chlamydia genus, in particular Chlamydia pneumoniae, by assaying the level of anti-Chlamydia antibodies in a biological sample from said individual.
 - 3. A pharmaceutical composition comprising at least one agent active against infection with a bacterium of the Chlamydia genus, in particular Chlamydia pneumoniae, or of at least one agent effective against the inflammatory effects of infection with Chlamydia, in a pharmaceutically acceptable carrier, for preventing and/or treating venous thromboembolic disease.
 - 4. The pharmaceutical composition according to claim 3, wherein said agent active against infection with a bacterium of the Chlamydia genus, in particular Chlamydia pneumoniae, is an antibiotic substance.
 - 5. The pharmaceutical composition according to claim 3, wherein said antibiotic substance active on bacteria of the Chlamydia genus, in particular Chlamydia pneumoniae, is chosen from the group consisting of macrolides, tetracyclines, fluoroquinolones and rifampicin.

6. The pharmaceutical composition according to claim 3, wherein said medicinal product is intended to prevent recurrences subsequent to a first venous thrombosis.

5

7. A method for preventing and/or treating venous thromboembolic disease, wherein a prophylactically or therapeutically effective amount of an agent active on bacteria of the Chlamydia genus, in combination with a pharmaceutically acceptable carrier, is administered to a patient requiring such a treatment.

10

NOS

8. A method according to claim 7, wherein said active agent is an antibiotic agent.

15

9. A method according to claim 7 intended for the prevention of recurrences subsequent to a first venous thrombosis.

20

and the transfer of the transf